Zileuton, a new efficient and safe systemic anti-acne drug
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Tissue inflammation is a major component of the acne process. Leukotriene B(4) (LTB(4)) is considered to be a major player in the development of tissue inflammation. Synthesis of LTB(4) is controlled by the enzyme 5-lipoxygenase. Since Zileuton blocks the activity of 5-lipoxygenase, experimental and clinical studies have been conducted to test mode of function, as well as efficacy and safety of this compound in the treatment of acne vulgaris. Human SZ95 sebocytes and inflammatory cells in vitro express the enzymes of the leukotriene pathway at mRNA and protein levels and enzymes involved in the biosynthesis of LTB(4) are activated in sebaceous glands of acne lesions. Pre-treatment of SZ95 sebocytes with Zileuton partially prevented short-term arachidonic acid-induced effects, such as induction of LTB(4), increase of neutral lipid content and stimulation of interlekin-6 release. Long-term treatment with Zileuton directly reduced the content of neutral lipids and interleukin-6 release from SZ95 seb ocytes. PPAR mRNA levels were not regulated by Zileuton. In a first pilot clinical study with 10 patients with papulopustular acne Zileuton 4 x 600 mg/d p.o. for 3 months decreased the acne severity index in a time-dependent manner being 41% of the initial score at week 12 (p < 0.05). This was mostly due to a decrease of the number of inflammatory lesions of 29% (p < 0.01). In addition, total sebum lipids significantly decreased (35%, p < 0.05) and the pro-inflammatory free fatty acids (22%) and lipoperoxides (26%) were markedly diminished in patients' sebum under treatment. The magnitude of clinical improvement strongly correlated with the reduction of total sebum lipids (p = 0.0009, r(2) = 0.81) and free fatty acids (p = 0.0003, r(2) = 0.82). In a further study, a 40-year-old female with mild disseminated sebaceous gland hyperplasia and seborrhea, responded with normalization of the casual skin surface lipids and similar reduction of facial sebum synthesis under treatment with Zileuton over 2weeks and-after a wash-out phase-low-dose isotretinoin (10 mg/2nd d) over 5 weeks. These data are in agreement with a phase II multicenter, clinical study in 101 patients with mild to moderate inflammatory facial acne conducted in the US, which showed a significant efficacy of Zileuton in a subset of patients with moderate acne, whereas those patients treated with Zileuton showed a significant mean decrease in inflammatory lesions compared to the placebo group. In all clinical studies, Zileuton was found to be safe and well tolerated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prostaglandins and Leukotrienes: Advances in Eicosanoid Biology
Funk, C. D. (2001) · Science · doi:10.1126/science.294.5548.1871 · Cited by 3,817
The PPARα–leukotriene B4 pathway to inflammation control
Devchand, P. R., Keller, H., Peters, J. M., Vazquez, M., Gonzalez, F. J., & Wahli, W. (1996) · Nature · doi:10.1038/384039a0 · Cited by 1,345
Chinetti, G., Fruchart, J.-C., & Staels, B. (2000) · Inflammation Research · doi:10.1007/s000110050622 · Cited by 954
Peroxisome proliferator-activated receptors in inflammation control
Delerive, P., Fruchart, J., & Staels, B. (2001) · Journal of Endocrinology · doi:10.1677/joe.0.1690453 · Cited by 755
Inflammatory Events Are Involved in Acne Lesion Initiation
Jeremy, A. H. T., Holland, D. B., Roberts, S. G., Thomson, K. F., & Cunliffe, W. J. (2003) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2003.12321.x · Cited by 541
Establishment and Characterization of an Immortalized Human Sebaceous Gland Cell Line (SZ95)1
Zouboulis, C. C., Seltmann, H., Orfanos, C. E., & Neitzel, H. (1999) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.1999.00771.x · Cited by 363
Self-citationAlestas, T., Ganceviciene, R., Fimmel, S., Müller-Decker, K., & Zouboulis, C. C. (2006) · Journal of Molecular Medicine · doi:10.1007/s00109-005-0715-8 · Cited by 269
Self-citationLigand Selectivity of the Peroxisome Proliferator-Activated Receptor α
Lin, Q., Ruuska, S. E., Shaw, N. S., Dong, D., & Noy, N. (1999) · Biochemistry · doi:10.1021/bi9816094 · Cited by 263
Frontiers in sebaceous gland biology and pathology
Zouboulis, C. C., Baron, J. M., Böhm, M., Kippenberger, S., Kurzen, H., Reichrath, J., & Thielitz, A. (2008) · Experimental Dermatology · doi:10.1111/j.1600-0625.2008.00725.x · Cited by 205
Self-citationIs Acne vulgaris a Genuine Inflammatory Disease?
Zouboulis, C. C. (2001) · Dermatology · doi:10.1159/000051771 · Cited by 130
Self-citation
Cited by
Tuchayi, S. M., Makrantonaki, E., Ganceviciene, R., Dessinioti, C., Feldman, S. R., & Zouboulis, C. C. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.29 · Cited by 432
Self-citationAcne is an inflammatory disease and alterations of sebum composition initiate acne lesions
Zouboulis, C. C., Jourdan, E., & Picardo, M. (2014) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.12298 · Cited by 286
Self-citationProtein Kinase C Isoforms Have Differential Roles in the Regulation of Human Sebocyte Biology
Géczy, T., Oláh, A., Tóth, B. I., Czifra, G., Szöllősi, A. G., Szabó, T., Zouboulis, C. C., Paus, R., & Bíró, T. (2012) · Journal of Investigative Dermatology · doi:10.1038/jid.2012.94 · Cited by 20
“, 2005), whereas the lipoxygenase inhibitor Zileuton markedly decreased it (Zouboulis et al., 2005; Zouboulis, 2009).”
ResultSelf-citation
Metadata
- Authors
- Zouboulis, C. C.
- Venue
- Dermato-Endocrinology
- Publisher
- Informa UK Limited
- Published
- 2009-05
- Volume
- 1
- Issue
- 3
- Pages
- 188-192
- ISSN
- 1938-1972 (ISSN-L)
- 1938-1980
- OpenAlex
- W2017584016
- Cited by
- 70
- References
- 10
- FWCI
- 4.83
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.